Comparison of Intra-arterial and Intravenous Thrombolysis for Ischemic Stroke with Hyperdense Middle Cerebral Artery Sign


Phase N/A Results

Trial Description

To compare intra-arterial thrombolysis (IAT) and intravenous thrombolysis (IVT)in ischemic stroke with hyperdense middle cerebral artery sign (HMCAS) patients.


  • Tissue plasminogen activator (Activase┬«)Drug
    Other Names: Alteplase; tPA
    Intervention Desc: Thrombolytic
  • Urokinase (Abbokinase┬«)Drug
    Intervention Desc: Thrombolytic agent
  • Mechanical Thrombectomy (Merci Retriever)Procedure
    Other Names: RNA Sequencing Analysis
    Intervention Desc: Extraction of cerebral emboli by using a novel retriever, microcatheter and balloon guide catheter system.

Trial Design

Prospective data collection.

Patient Involvement

All Bernese patients were treated with IAT using urokinase (500,000 to 1,200,000 IU) and mechanical clot disruption up to 6 hours after symptom onset. All Zurich patients were treated with IVT using rt-PA (0.9 mg/kg body weight) up to 3 hours after symptom onset. Data from the two stroke units were then compared.


Type Measure Time Frame Safety Issue
Primary Mortality rate and the modified Rankin Scale (mRS), dichotomized at three months into favorable (mRS 0-2) and unfavorable (mRS 3-6).